The first-generation AAV2 vector was used in the first gene therapy clinical trial targeting the liver for the treatment of hemophilia B. There were related risk reports indicating that when the AAV vector dose was increased in gene therapy, CD8+ T cells responded to the capsid protein, causing the AAV vector to be cleared by the human immune system before cell transduction [144]. Here, CD8A is linked to hemophilia B.